Digilab Expects Patent for Alzheimer's Peptide Marker in Two Months; Eyes Dx | GenomeWeb
Digilab BioVision last week said it may soon receive patent protection for one of 30 peptide biomarkers it discovered that it believes can help diagnose Alzheimer’s disease.
While numerous researchers and companies hunt for protein biomarkers linked to neurodegenerative diseases, less work has been done to identify peptide biomarkers, even though some experts assert that peptides can provide greater indication of disease.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.